60 related articles for article (PubMed ID: 17701003)
1. A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
Farley JH; Brady WE; O'Malley D; Fujiwara K; Yonemori K; Bonebrake A; Secord AA; Stephan JM; Walker JL; Nam JH; Birrer MJ; Gershenson DM
Gynecol Oncol; 2022 Dec; 167(3):423-428. PubMed ID: 36244829
[TBL] [Abstract][Full Text] [Related]
2. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
3. Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens.
Chen CA; Chiang CJ; Chen YY; You SL; Hsieh SF; Tang CH; Cheng WF
J Gynecol Oncol; 2018 Jan; 29(1):e16. PubMed ID: 29185274
[TBL] [Abstract][Full Text] [Related]
4. Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives.
Matsuzaki S; Yoshino K; Ueda Y; Matsuzaki S; Kakuda M; Okazawa A; Egawa-Takata T; Kobayashi E; Kimura T
Cancer Cell Int; 2015; 15():117. PubMed ID: 26675567
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment of early stage and rare histological variants of epithelial ovarian cancer.
Cont NT; Ferrero A; Peccatori FA; D'Alonzo M; Codacci-Pisanelli G; Colombo N; Biglia N
Ecancermedicalscience; 2015; 9():584. PubMed ID: 26557882
[TBL] [Abstract][Full Text] [Related]
6. A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age.
Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
Int J Clin Oncol; 2014 Oct; 19(5):921-7. PubMed ID: 24306200
[TBL] [Abstract][Full Text] [Related]
7. Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma.
Machida S; Sato T; Fujiwara H; Saga Y; Takei Y; Taneichi A; Nonaka H; Suzuki M
Oncol Lett; 2012 Nov; 4(5):1017-1022. PubMed ID: 23162643
[TBL] [Abstract][Full Text] [Related]
8. Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents.
Takatori E; Shoji T; Kumagai S; Sawai T; Kurose A; Sugiyama T
J Ovarian Res; 2012 Jun; 5(1):16. PubMed ID: 22691365
[TBL] [Abstract][Full Text] [Related]
9. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.
Mannel RS; Brady MF; Kohn EC; Hanjani P; Hiura M; Lee R; Degeest K; Cohn DE; Monk BJ; Michael H
Gynecol Oncol; 2011 Jul; 122(1):89-94. PubMed ID: 21529904
[TBL] [Abstract][Full Text] [Related]
11. POU6F1 is the transcription factor that might be involved in cell proliferation of clear cell adenocarcinoma of the ovary.
Yoshioka N; Suzuki N; Uekawa A; Kiguchi K; Ishizuka B
Hum Cell; 2009 Nov; 22(4):94-100. PubMed ID: 19874398
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
Takano M; Kikuchi Y; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Sugiyama T
Oncol Rep; 2006 Dec; 16(6):1301-6. PubMed ID: 17089053
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Sugiyama T; Okamoto A; Enomoto T; Hamano T; Aotani E; Terao Y; Suzuki N; Mikami M; Yaegashi N; Kato K; Yoshikawa H; Yokoyama Y; Tanabe H; Nishino K; Nomura H; Kim JW; Kim BG; Pignata S; Alexandre J; Green J; Isonishi S; Terauchi F; Fujiwara K; Aoki D
J Clin Oncol; 2016 Aug; 34(24):2881-7. PubMed ID: 27400948
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Takakura S; Takano M; Takahashi F; Saito T; Aoki D; Inaba N; Noda K; Sugiyama T; Ochiai K;
Int J Gynecol Cancer; 2010 Feb; 20(2):240-7. PubMed ID: 20169667
[TBL] [Abstract][Full Text] [Related]
15. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
Takano M; Tsuda H; Sugiyama T
J Exp Clin Cancer Res; 2012 Jun; 31(1):53. PubMed ID: 22655678
[TBL] [Abstract][Full Text] [Related]
16. Advanced ovarian cancer.
van der Burg ME
Curr Treat Options Oncol; 2001 Apr; 2(2):109-18. PubMed ID: 12057129
[TBL] [Abstract][Full Text] [Related]
17. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
Int J Clin Oncol; 2007 Aug; 12(4):256-60. PubMed ID: 17701003
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
